Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

Activating TP53 by Dual Inhibition of MDMX and MDM2

Ulrich G. Steidl, MD PhD

Blood (2019) 134 (Supplement_1): SCI-14.

https://doi.org/10.1182/blood-2019-121097

Published: 2019

Journal Articles

BCAS2 is essential for hematopoietic stem and progenitor cell maintenance during zebrafish embryogenesis

Blood (2019) 133 (8): 805–815.

https://doi.org/10.1182/blood-2018-09-876599

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A Sallman, MD, Uma Borate, MD, Elizabeth H. Cull, MD, William B. Donnellan, MD, Rami S. Komrokji, MD, Ulrich G. Steidl, MD PhD, Maria M Corvez, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amit Verma, MD

Blood (2018) 132 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2018-99-118780

Published: 2018

Journal Articles

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Andrei R. Shustov, MD, Amitkumar Mehta, MD, Lubomir Sokol, MD PhD, Luis A. Carvajal, PhD, Vincent Guerlavais, PhD, Manoj Samant, PhD, Narayana Narasimhan, PhD, David Sutton, BSc, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Ronald Korn, MD PhD

Blood (2018) 132 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2018-99-119489

Published: 2018

Journal Articles

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Raphael Koch, MD, Amanda L Christie, BS, Noriaki Yoshida, MD PhD, Samuel Y. Ng, MDPhD, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, MD, Eric Jacobsen, MD, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, PhD, D. Allan Annis, Manuel A. Aivado, MD PhD, David M. Weinstock, MD

Blood (2017) 130 (Supplement 1): 571.

https://doi.org/10.1182/blood.V130.Suppl_1.571.571

Published: 2017

Journal Articles

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Bridget Marcellino, MD PhD, Joseph Tripodi, Min Lu, PhDMD, Heidi Kosiorek, MS, John Mascarenhas, MD, Raajit K. Rampal, MD PhD, Amylou Constance Dueck, PhD, Ronald Hoffman, MD, Vesna Najfeld, PhD

Blood (2017) 130 (Supplement 1): 204.

https://doi.org/10.1182/blood.V130.Suppl_1.204.204

Published: 2017

Journal Articles

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Luis A. Carvajal, PhD, Daniela Ben-Neriah, B.S, Adrien Senecal, PhD, Lumie Bernard, M.S, Swathi-Rao Narayanagari, M.S, Charles Kenworthy, B.S, Victor Thiruthuvanathan, M.S, Vincent Guerlavais, PhD, D. Allen Annis, PhD, Boris Bartholdy, PhD, Britta Will, PhD, Jesus Anampa, MD, Ioannis Mantzaris, MD, Manuel A. Aivado, MD PhD, Robert H Singer, PhD, Robert Coleman, PhD, Amit Verma, MD, Ulrich G. Steidl, MDPhD

Blood (2017) 130 (Supplement 1): 795.

https://doi.org/10.1182/blood.V130.Suppl_1.795.795

Published: 2017

Journal Articles

Genetic Ablation or Pharmacological Inhibition of PRMT5 Affects Maintenance of Genomic Integrity in Hematopoietic Stem Cells

Darren Qiancheng Tan, BS, Desmond Wai Loon Chin, PhD, Ying Li, Ayako Nakamura-Ishizu, MD PhD, Henry Yang, PhD, Toshio Suda, MDPhD

Blood (2017) 130 (Supplement 1): 711.

https://doi.org/10.1182/blood.V130.Suppl_1.711.711

Published: 2017

Journal Articles

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Carolina Terragna, PhD, Marina Martello, Enrica Borsi, PhD, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Brioli Annamaria, MD, Beatrice Anna Zannetti, MD, Flores Dico, Nicoletta Testoni, BS, Giulia Marzocchi, PhD, Katia Mancuso, MD, Serena Rocchi, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1855.

https://doi.org/10.1182/blood.V122.21.1855.1855

Published: 2013

Journal Articles

A Splicing Variant of MDM4 Overexpression Plays an Indicator of p53 Aberrations and Marks a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

Wei Xu, Ling Liu, Lei Fan, M.D., Ph.D., Li Wang, M.D., Run Zhang, M.D., Ji Xu, M.D.

Blood (2012) 120 (21): 4564.

https://doi.org/10.1182/blood.V120.21.4564.4564

Published: 2012

Journal Articles

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Blood (2012) 120 (21): 1810.

https://doi.org/10.1182/blood.V120.21.1810.1810

Published: 2012

Journal Articles

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Carolina Terragna, PhD, Marina Martello, Sandra Durante, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Giulia Perrone, MD, Beatrice Anna Zannetti, MD, Enrica Borsi, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2011) 118 (21): 3935.

https://doi.org/10.1182/blood.V118.21.3935.3935

Published: 2011

Journal Articles

The Role of Mdm2 In Inactivation of the P53 Pathway In APL

Julia Abramowitz, Tzahi Neuman, Yoav Smith, Rania Samman, Alex Gural, Riki Perlman, Dina Ben-Yehuda

Blood (2010) 116 (21): 5111.

https://doi.org/10.1182/blood.V116.21.5111.5111

Published: 2010

Journal Articles

Mdm2 and Mdmx Are Not the Major Negative Regulators of the p53 Pathway in Myeloid Leukemias.

Julia Abramowitz, Tzahi Neuman, Rania Samman, Riki Perlman, Dina Ben-Yehuda

Blood (2009) 114 (22): 5046.

https://doi.org/10.1182/blood.V114.22.5046.5046

Published: 2009

Journal Articles

A Stapled p53 Helix Targets HDMX to Overcome Nutlin-3 Resistance and Reactivate the p53 Tumor Suppressor Pathway in Cancer

Federico Bernal, Ph.D., Mark Wade, Ph.D., Amy M. Silverstein, Gregory L. Verdine, Ph.D., Geoffrey M. Wahl, Ph.D., Loren D. Walensky, M.D., Ph.D.

Blood (2008) 112 (11): 2645.

https://doi.org/10.1182/blood.V112.11.2645.2645

Published: 2008

Journal Articles

Novel Small Molecule MDM2 Inhibitor MI-63 Induces p53-Dependent Apoptosis in AML Cell Lines.

Ismael Samudio, PhD, Martin Dietrich, M.D., Paul Corn, M.D.; PhD, Dajun Yang, M.D.,Ph.D, Gautam Borthakur, M.D

Blood (2006) 108 (11): 2596.

https://doi.org/10.1182/blood.V108.11.2596.2596

Published: 2006

Journal Articles

Distinct roles of Mdm2 and Mdm4 in red cell production

Marion Maetens, Gilles Doumont, Sarah De Clercq, Sarah Francoz, Pascal Froment, Eric Bellefroid, Ursula Klingmuller, Guillermina Lozano, Jean-Christophe Marine

Blood (2006) 109 (6): 2630–2633.

https://doi.org/10.1182/blood-2006-03-013656

Published: 2006

Includes: Supplemental data

Journal Articles

MDMX Is Widely Expressed in Adult Pre-Cursor B Cell B Acute Lymphoblastic Leukemia and Is a Potential Therapeutic Target.

Xin Han, MD, Guillermo Garcia-Manero, MD, Timothy McDonnell, MD, PhD, Gullermina Lozano, Ph.D, L. Jeffrey Medeiros, MD., Gary Rosner, PHS, Kimberly J. Hayes, BS, Carlos E. Bueso-Ramos, MD. Ph.D.

Blood (2005) 106 (11): 3280.

https://doi.org/10.1182/blood.V106.11.3280.3280

Published: 2005

NARROW

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Activating TP53 by Dual Inhibition of MDMX and MDM2

BCAS2 is essential for hematopoietic stem and progenitor cell maintenance during zebrafish embryogenesis

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Genetic Ablation or Pharmacological Inhibition of PRMT5 Affects Maintenance of Genomic Integrity in Hematopoietic Stem Cells

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

A Splicing Variant of MDM4 Overexpression Plays an Indicator of p53 Aberrations and Marks a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

The Role of Mdm2 In Inactivation of the P53 Pathway In APL

Mdm2 and Mdmx Are Not the Major Negative Regulators of the p53 Pathway in Myeloid Leukemias.

A Stapled p53 Helix Targets HDMX to Overcome Nutlin-3 Resistance and Reactivate the p53 Tumor Suppressor Pathway in Cancer

Novel Small Molecule MDM2 Inhibitor MI-63 Induces p53-Dependent Apoptosis in AML Cell Lines.

Distinct roles of Mdm2 and Mdm4 in red cell production

MDMX Is Widely Expressed in Adult Pre-Cursor B Cell B Acute Lymphoblastic Leukemia and Is a Potential Therapeutic Target.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only